Chemical assembly systems: Layered control for divergent, continuous, multistep syntheses of active pharmaceutical ingredients

Angewandte Chemie - International Edition

Volumn 54, Issue 2, 2015, Pages 678-682

  Ghislieri, Diego ^a   Gilmore, Kerry ^a   Seeberger, Peter H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Active pharmaceutical ingredients; Chemical assembly; Divergent synthesis; Flow chemsitry; amino acids

Indexed keywords

AMINO ACIDS; ASSEMBLY; BATCH DATA PROCESSING; CHEMICAL REACTIONS; CUSTOMER SATISFACTION;

ACTIVE PHARMACEUTICAL INGREDIENTS; BLOCKBUSTER DRUGS; CHEMICAL ASSEMBLY; CONTINUOUS CHEMICAL PROCESS; CONTINUOUS PRODUCTION; DIVERGENT SYNTHESIS; FLOW CHEMSITRY; ORDER OF REACTION;

SYNTHESIS (CHEMICAL);

DRUG;

PHARMACEUTICAL PREPARATIONS;

EID: 84922798889     PISSN: 14337851     EISSN: 15213773     Source Type: Journal    
DOI: 10.1002/anie.201409765     Document Type: Article

References (53)

1. D. J. C. Constable, P. J. Dunn, J. D. Hayler, G. R. Humphrey, J. L. Leazer, Jr., R. J. Linderman, K. Lorenz, J. Manley, B. A. Pearlman, A. Wells, A. Zaksh, T. Y. Zhang, Green Chem. 2007, 9, 411-420.
2. C. Vaxelaire, P. Winter, M. Christmann, Angew. Chem. Int. Ed. 2011, 50, 3605-3607
3. H. C. Kolb, M. G. Finn, K. B. Sharpless, Angew. Chem. Int. Ed. 2001, 40, 2004-2021;
4. Angew. Chem. 2001, 113, 2056-2075.
5. J. F. Hartwig, Science 2002, 297, 1653-1654.
6. I. W. Davies, C. J. Welch, Science 2009, 325, 701-704.
7. a) J.-i. Yoshida, Y. Takahashi, A. Nagaki, Chem. Commun. 2013, 49, 9896-9904;
8. b) D. Webb, T. F. Jamison, Chem. Sci. 2010, 1, 675-680.
9. a) I. R. Baxendale, S. V. Ley, A. C. Mansfield, C. D. Smith, Angew. Chem. Int. Ed. 2009, 48, 4017-4021;
10. Angew. Chem. 2009, 121, 4077-4081;
11. b) H. R. Sahoo, J. G. Kralj, K. F. Jensen, Angew. Chem. Int. Ed. 2007, 46, 5704-5708;
12. Angew. Chem. 2007, 119, 5806-5810;
13. c) S. Suga, M. Okajima, K. Fujuwara, J.-i. Yoshida, J. Am. Chem. Soc. 2001, 123, 7941-7942.
14. a) J. Hartwig, S. Ceylan, L. Kupracz, L. Coutable, A. Kirschning, Angew. Chem. Int. Ed. 2013, 52, 9813-9817;
15. Angew. Chem. 2013, 125, 9995-9999;
16. b) M. D. Hopkin, I. R. Baxendale, S. V. Ley, Chem. Commun. 2010, 46, 2450-2452;
17. c) A. R. Bogdan, S. L. Poe, D. C. Kubis, S. J. Broadwater, D. T. McQuade, Angew. Chem. Int. Ed. 2009, 48, 8547-8550;
18. Angew. Chem. 2009, 121, 8699-8702;
19. d) M. Viviano, T. N. Glasnov, B. Reichart, G. Tekautz, C. O. Kappe, Org. Process Res. Dev. 2011, 15, 858-870;
20. e) D. R. Snead, T. F. Jamison, Chem. Sci. 2013, 4, 2822-2827;
21. f) L. Kupracz, A. Kirschning, Adv. Synth. Catal. 2013, 355, 3375-3380;
22. g) M. D. Hopkin, I. R. Baxendale, S. V. Ley, Org. Biomol. Chem. 2013, 11, 1822-1839.
23. J. C. Pastre, D. L. Browne, S. V. Ley, Chem. Soc. Rev. 2013, 42, 8849-8869.
24. S. Mascia, P. L. Heider, H. Zhang, R. Lakerveld, B. Benyahia, P. I. Barton, R. D. Braatz, C. L. Cooney, J. M. B. Evans, T. F. Jamison, K. F. Jensen, A. S. Myerson, B. L. Trout, Angew. Chem. Int. Ed. 2013, 52, 12359-12363;
25. Angew. Chem. 2013, 125, 12585-12589.
26. L. Malet-Sanz, F. Susanne, J. Med. Chem. 2012, 55, 4062-4098.
27. a) M. Burns, S. Essafi, J. R. Bame, S. P. Bull, M. P. Webster, S. Balieu, J. W. Dale, C. P. Butts, J. N. Harvey, V. K. Aggarwal, Nature 2014, 513, 183-188;
28. A. G. Salles, Jr., S. Zarra, R. M. Turner, J. R. Nitschke, J. Am. Chem. Soc. 2013, 135, 19143-19146.
29. a) F. Lévesque, P. H. Seeberger, Org. Lett. 2011, 13, 5008-5011;
30. b) D. B. Ushakov, K. Gilmore, D. Kopetzki, D. T. McQuade, P. H. Seeberger, Angew. Chem. Int. Ed. 2014, 53, 557-561;
31. Angew. Chem. 2014, 126, 568-572;
32. c) D. B. Ushakov, K. Gilmore, P. H. Seeberger, Chem. Commun. 2014, 50, 12649-12651.
33. a) F. Lévesque, P. H. Seeberger, Angew. Chem. Int. Ed. 2012, 51, 1706-1709;
34. Angew. Chem. 2012, 124, 1738-1741;
35. b) K. Gilmore, D. Kopetzki, J. W. Lee, Z. Horváth, D. T. McQuade, A. Seidel-Morgenstern, P. H. Seeberger, Chem. Commun. 2014, 50, 12652-12655.
36. a) Z. He, T. F. Jamison, Angew. Chem. Int. Ed. 2014, 53, 3353-3357;
37. Angew. Chem. 2014, 126, 3421-3425.
38. J. S. Carey, D. Laffan, C. Thomson, M. T. Williams, Org. Biomol. Chem. 2006, 4, 2337-2347.
39. P. L. Anelli, C. Biffi, F. Montanari, S. Quici, J. Org. Chem. 1987, 52, 2559-2562.
40. J. G. Kralj, H. R. Sahoo, K. F. Jensen, Lab Chip 2007, 7, 256-263.
41. a) D. Webb, T. F. Jamison, Org. Lett. 2012, 14, 2465-2467;
42. b) V. Solodenko, U. Kunz, G. Jas, A. Kirschning, Bioorg. Med. Chem. Lett. 2002, 12, 1833.
43. M. Tarleton, A. McClusky, Tetrahedron Lett. 2011, 52, 1583-1586.
44. D. E. Griswold, E. F. Webb, J. Breton, J. R. White, P. J. Marshall, T. J. Torphy, Inflammation 1993, 17, 333-344.
45. Y. Shen et al., U.S. Pat. Appl. Publ. 20030186943, 2003.
46. The only change to the reaction conditions required occurs in module 3 for trisubstituted alkenes (gabapentin precursor); see the Supporting Information.
47. N. Attal, G. Cruccu, R. Baron, M. Haanpää, P. Hansson, T. S. Jensen, T. Nurmikko, European Federation of Neurological Societies, Eur. J. Neurol. 2010, 17, 1113-1123. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
48. T. M. Wensel, K. W. Powe, M. E. Cates, Ann. Pharmacother. 2012, 46, 424-429.
49. The active enantiomer is (S)-pregabalin. While this system represents a racemic synthesis, the enatiopure material can easily be obtained through co-crystallization with (S)-mandelic acid; see the Supporting Information for details.
50. K. L. Goa, E. M. Sorkin, Drugs 1993, 46, 409-427.
51. The overall yield of gabapentin with respect to the other γ-amino acids can be attributed to incomplete conversion in module 3; see Table S6 and related discussion in the Supporting Information for details.
52. A. Mann, T. Boulanger, B. Brandau, F. Durant, G. Evrard, M. Heaulme, E. Desaulles, C. G. Wermuth, J. Med. Chem. 1991, 34, 1307-1313.
53. I. S. Sytinsky, A. T. Soldatenkov, Prog. Neurobiol. 1978, 10, 89-133.